Slide 1: 7M2025 Business Updates
7M2025 BUSINESS UPDATES IMEXPHARM CORPORATION
Slide 2: Sustained ETC growth offset temporary July OTC dip due to customer stockpiling
Sustained ETC growth offset temporary July OTC dip due to customer stockpiling July net revenue ▪ Revenue from all EU-GMP factories VND 180 bn recorded double-digit growth, with IMP4 ▲ 13% YoY achieving the highest increase at 67% ETC ▲ 27% YoY (*) year-over-year. ▪ ETC revenue remained on a solid g
Slide 3: Resilient performance in 7M, well-positioned for full-year targets
Resilient performance in 7M, well-positioned for full-year targets 7M net revenue VND 1,407 bn ▪ We have achieved VND 1,407 billion in net revenue, representing 53% of the ▲ 21% YoY ETC ▲ 25% YoY (*) AGM target. ▪ Both OTC and ETC channels recorded 7M EBITDA strong growth, each rising by 25% year- o
Slide 4: Business highlights
Business highlights Teamed up with Pharmacity to deliver an intensive training Kicked off the iHRP integration project to enhance HR program for over 100 pharmacists in Ho Chi Minh City operations in partnership with FPT Corporation 4
Slide 5: Stock performance
Stock performance % 160 IMP stock price 120 Weighted avg share price of top 6 pharma companies by 80 revenue 40 VNIndex 0 -40 IMP DHG TRA DHT DBD DMC YTD avg. daily trading volume 200,948 23,770 4,651 33,413 289,777 10,068 YTD stock performance 11% (2%) (13%) (9%) (4)% (7%) Daily trading volume in 7
Slide 6: Disclaimer
Disclaimer The contents of the IR Newsletter are intended to provide information to institutional investors as well as individual investors of Imexpharm Corporation (Hose: IMP). IMP strives to ensure transparency, completeness, and accuracy of the information in this newsletter. IMP is exempt from a
Slide 7: Thank You
Thank You For further discussion, please contact our IR team ir@imexpharm.com 7